89 results
424B2
PLSE
Pulse Biosciences Inc
4 Jun 24
Prospectus for primary offering
4:05pm
evaluating the safety and efficacy of the Company’s CellFX nsPFA Cardiac Clamp and CellFX nsPFA 360° Cardiac Catheter for the treatment of atrial … ongoing investment in current and future clinical studies evaluating the safety and efficacy of the Company’s CellFX nsPFA Cardiac Clamp and CellFX
POS AM
PLSE
Pulse Biosciences Inc
28 May 24
Prospectus update (post-effective amendment)
5:19pm
evaluating the safety and efficacy of the Company’s CellFX nsPFA Cardiac Clamp and CellFX nsPFA 360° Cardiac Catheter for the treatment of atrial fibrillation … in current and future clinical studies evaluating the safety and efficacy of the Company’s CellFX nsPFA Cardiac Clamp and CellFX nsPFA 360° Cardiac
8-K
EX-99.1
PLSE
Pulse Biosciences Inc
20 May 24
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
4:10pm
, statements concerning early clinical successes and whether they are predictive of the safety and efficacy of any medical device such as the CellFX
8-K
EX-99.1
PLSE
Pulse Biosciences Inc
15 May 24
Pulse Biosciences Enhances Executive Leadership Team
9:05am
to continue current operations as planned, statements concerning early clinical successes and whether they are predictive of the safety and efficacy of any
8-K
EX-99.1
PLSE
Pulse Biosciences Inc
9 May 24
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
9:09am
with our unique proprietary technology, giving them the potential to set new standards for safety and efficacy as well as decreased workflow time from … clinical successes and whether they are predictive of the safety and efficacy of any medical device such as the CellFX nsPFA Percutaneous Electrode System
8-K
EX-99.1
29m1bvzo312ucvv
7 May 24
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
4:14pm
8-K
EX-99.1
3g1w8oxik1q 82hpkdnv
28 Mar 24
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
4:18pm
8-K
EX-99.1
kp38r0 yno6
11 Mar 24
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
9:10am
8-K
EX-99.1
eajkq rdby
14 Feb 24
Other Events
9:22am
8-K
EX-99.1
edrnk00w3t81w
2 Jan 24
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
9:20am
8-K
EX-99.1
nf2d04v6fss5qjbt5pqp
20 Dec 23
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
9:06am
8-K
roqktjz9h3
27 Nov 23
Regulation FD Disclosure
9:08am